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Abstract
Background: Prostate cancer is a leading disease affecting men worldwide. Conflicting evidence within
the literature provides little guidance to men contemplating whether or not to be screened for prostate
cancer. This systematic review aimed to determine whether decision aids about early detection of pros-
tate cancer improve patient knowledge and decision making about whether to undergo prostate-
specific antigen testing.
Methods: Medline, EMBASE, CINAHL, PsychINFO, Cochrane Database of Systematic Reviews,
Database of Abstracts of Reviews of Effects and Health Technology Assessment databases up until
March 2014 were searched. All included randomised controlled trials were assessed for methodolog-
ical quality. Clinical selection and assessment heterogeneity among studies prevented the pooling of
data for meta-analyses. Descriptive analyses of all included studies and comparison were performed.
Results: A total of 13 randomised controlled trials met the inclusion criteria. Significant heterogene-
ity was present for the design and implementation of decision aids including comparative interven-
tions and outcomes. Eight studies were of a low methodological quality, with the remaining five of
medium quality. Improvements in patient knowledge following use of a decision aid were demon-
strated by 11 of the 13 included studies. Seven of 10 studies demonstrated a reduction in decisional
conflict/distress. Three of four studies demonstrated no difference between a decision aid and informa-
tion only in reducing decisional uncertainty. Three of five studies demonstrated an increase in deci-
sional satisfaction with use of a decision aid.
Conclusions: Decision aids increase patient knowledge and confidence in decision making about
prostate cancer testing. Further research into effective methods of implementation is needed.
Copyright © 2015 John Wiley & Sons, Ltd.
Introduction
Prostate cancer is a leading cancer affecting men, with the
incidence second only to lung cancer worldwide [1]. It is
the most commonly diagnosed cancer in men living in de-
veloped countries and sixth commonest cancer in men liv-
ing in developing countries [1]. Geographical variation in
incidence rates has been attributed in part to different ap-
plications of screening and testing for prostate cancer
[2]. Age, ethnicity and familial history are all accepted
as non-modifiable risk factors for prostate cancer [3]. Both
the prostate-specific antigen (PSA) test and the digital rec-
tal examination are commonly used as primary diagnostic
tests for prostate cancer. Yet testing for prostate cancer in
individual patients is a controversial issue, as population
screened randomised controlled trials (RCTs) have shown
conflicting survival benefits [4].
Screening for prostate cancer aims to detect the disease
at an early stage and provide the patient with a choice of
treatment options including variations of surgery,
Copyright © 2015 John Wiley & Sons, Ltd.
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radiotherapy and delayed or non-intervention [4]. The ef-
fectiveness of the PSA test remains controversial, as there
is no single cut-off for further investigation with biopsy,
which provides both high sensitivity and specificity. The
commonly used threshold of 4.1 ng/mL yields a low
false-positive rate (6.2%), but has a low sensitivity, detect-
ing cancer in one out of five men [5]. Decreasing the
threshold for biopsy would increase the proportion of
men diagnosed with prostate cancer, but would also in-
crease the rate of false-positives. Furthermore, lowering
the threshold is associated with diagnosing more men with
clinically insignificant cancer than when a higher thresh-
old is used. Consequently, implementation of PSA testing
in the general asymptomatic population is associated with
significant overdiagnosis and overtreatment [6]. This
carries the risk of significant long lasting side effects in-
cluding incontinence, erectile dysfunction and psychoso-
cial implications on quality of life [7,8].
Given the relative benefits and harms of screening for
prostate cancer, many peak medical bodies have recom-
mended a shared approach to decisionmaking on PSA test-
ing between patient and clinician [9–12]. Central to this
shared decision-making process is ensuring that the patient
is properly informed about the benefits and limitations of
the medical intervention on offer. Decision aids aim to pro-
vide people with an opportunity to make an informed deci-
sion about a screening or treatment intervention through
the provision of information about the benefits, limitations
and uncertainty associated with the choice. Decision aids
differ from usual health education materials because the
content of decision aids is focused to make explicit the
decision being considered, with an emphasis on
personalising the focus of the user to the options and sub-
sequent outcomes [13]. Decision aids, or decision support
interventions, may be implemented in a variety of formats
including written hardcopy (e.g. pamphlet/booklet), multi-
media (e.g. computer, DVD, internet-based) or in-person
support (e.g. counselling via nurse or physician) [14].
The primary focus of decision aids is to ensure that the user
is able to improve his/her decision-making process in order
to reach a high-quality, well-informed decision [13].
The aim of this study was to systematically review the
literature to identify whether a decision aid (or decision
support intervention) about PSA testing for early detection
of prostate cancer improves decision making and knowl-
edge compared with usual care for men without evidence
of prostate cancer.
Methods
Study selection
Randomised controlled trials that included men at average
or high risk of developing prostate cancer, without evi-
dence of prostate cancer and considering a PSA test were
eligible for inclusion in this systematic review. A study
was eligible if it assessed a decision support intervention,
a decision aid or tailored information (including risk com-
munication) about PSA testing for early detection of pros-
tate cancer. Comparisons were made with usual care, no
intervention, an attention control or provision of simple
non-personalised information.
A decision support intervention/decision aid was de-
fined as an intervention designed to help people make spe-
cific and deliberative choices among options (including the
status quo) by providing (at the minimum) the following:
• information on the options and outcomes relevant to
a person’s health status; and
• implicit methods to clarify values.
The aid also may have included the following:
• information on the disease/condition; costs associ-
ated with options; probabilities of outcomes tailored
to personal health risk factors;
• an explicit values clarification exercise;
• information on others’ opinions; a personalised rec-
ommendation on the basis of clinical characteristics
and expressed preferences; and
• guidance or coaching in the steps of making and
communicating decisions with others [14].
Tailored information was defined as an intervention
through which information is given to patients or individ-
uals at risk of developing cancer where
• the main objective of the information is to inform
people about cancer risks, screening options, cancer
genetic counselling and DNA testing;
• the information is delivered by computer (e.g. CD-
ROM or internet) or as printed material (e.g. letter
or leaflet);
• the information is tailored based on more than one
variable using algorithms [15].
Non-tailored information was defined as the provision of
information on risks and benefits of testing in a screening
context or discussion of risks and benefits of different options
in a treatment context but does not include tailoring for the
individual and does not include specific decision-making ad-
vice about strategies such as, and in particular, weighing up
pros and cons or consideration of personal values.
The primary outcome of the systematic review was dif-
ferences in patient decision making; comprising decisional
satisfaction, decision-related distress (including decisional
conflict and anxiety) and decisional uncertainty. Second-
ary outcomes included changes in patient knowledge.
Studies needed to be written in English and published af-
ter the 31st of December 1989. Conference proceedings
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identified by the literature searches were included if they
met the inclusion criteria.
Data sources
Medline (1990 to current), Excerpta Medica dataBase
(EMBASE) (1990 to current), Cumulative Index to Nurs-
ing and Allied Health Literature (CINAHL) (1990 to cur-
rent), PsychINFO (1990 to current), Cochrane Database
of Systematic Reviews (2005 to current), Database of Ab-
stracts of Reviews of Effects and Health Technology As-
sessment databases up until March 2014 were searched
using text terms and, where available, database specific
subject headings. The search strategy employed for each
of the databases is supplied in the supplementary materials.
Relevant recent (2005 onwards) guidelines were identified
by scanning the citations identified by the literature search
and searching the National Guideline Clearinghouse
(http://guideline.gov) and the Guidelines Resource Centre
(www.cancerview.ca).
Two reviewers (S.H. and D.S.) screened the titles and
abstracts of all articles returned from the search strategy.
Full-text copies of articles were sourced in the event that
a decision to include/exclude an article based on informa-
tion presented in the title or abstract of the article was not
sufficient. All articles that met the pre-specified study se-
lection criteria were included in the review.
Data collection, extraction and assessment of quality
Data was extracted by two reviewers (S.H. and D.S.)
from studies included in the review as per the Cochrane
Collaboration’s double-data collection and extraction
methodology [16]. Data extracted included study design
and setting, numbers and demographic details of study
participants, methodological descriptions of the interven-
tion and comparisons and results. The methodological
quality of each study was assessed independently by two
reviewers (S.H. and D.S.): each was assessed as to the ad-
equacy of blinding, allocation concealment and intention-
to-treat (ITT) analysis [17,18]. Methodological quality of
studies was determined as follows:
• High quality: a review that received two for three
main criteria (double-blinding, concealment of treat-
ment allocation schedule, inclusion of all randomised
participants in analysis (i.e. ITT))
• Medium quality: Received two and/or one for all
three main criteria
• Low quality: Received 0 for all three criteria or 0
and one for all three criteria or received 0 for any
of the three criteria.
Information about generation of allocation sequences
was considered as additional information and not consid-
ered when calculating the overall quality score [17,18].
Data analysis
Because of the clinical heterogeneity between studies in
terms of how outcomes were measured, pooling of
published data for meta-analyses was not possible. Such
outcomes may be pooled using a standardised mean differ-
ence; however, this method assumes that the differences in
standard deviations among studies reflect differences in
measurement scales and not real differences in variability
among study populations [16]. This assumption is prob-
lematic in this review, given the heterogeneity between
study participants. Additionally, comparisons differed,
the design and implementation of the interventions were
varied, and controls ranged from provision of generic in-
formation to no intervention. A descriptive analysis of all
studies was performed, given the possible impact of this
clinical heterogeneity in pooling such diverse data.
Results
Description of studies
A total of 737 citations were identified through the search of
the literature, of which 13 articles met the inclusion criteria
(Figure 1). The combined Medline and PsycINFO search
identified 512 citations, the EMBASE search identified an
additional 203 citations, the CINAHL search 16 citations
and the search of the Cochrane Database of Systematic Re-
views, Database of Abstracts of Reviews of Effects and
Health Technology Assessment database identified an addi-
tional 6 citations. Titles and abstracts were examined and 67
articles were retrieved for a more detailed evaluation. An
additional 12 potential citations were identified from the ref-
erence list of retrieved articles. A total of 66 articles were
excluded, of which 11 were review articles, 14 were not
an RCT, 4 had participants not meeting the inclusion
criteria, 2 were not relevant to prostate cancer, 15 did not
meet the criteria for the intervention, 5 did not meet the
criteria for the control, 12 did not report relevant outcomes
and 3 were duplicate or publications reporting pilot data.
Studies were only included if sufficient information was
available to determine whether the intervention met the
criteria of the aforementioned definitions. In particular,
for decision aids, the method for clarifying men’s values
about undergoing the PSA test had to be described ade-
quately. Studies examining the effect of a decision aid that
did not meet these criteria or those that provided insuffi-
cient information to allow for assessment of adequacy of
the decision aid were excluded. Study characteristics in-
cluding methodology, participants, interventions and out-
comes for included studies are detailed in Table 1.
Reasons for the exclusion of studies are detailed in the
supplementary document.
A total of 6909 men participated in the 13 included stud-
ies. Participants ranged in age from 40 to at least 80 years
of age. Nine of the studies were based in the USA, with
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three in Australia and one in the UK. Seven of the studies
recruited men from a primary care setting, two from com-
munity settings and one each from a Department of
Veteran’s Affairs (DVA) outpatient clinic, pre-registered
screening project, work sites and health insurance regis-
tries. Two studies were in populations at higher risk of
prostate cancer [19,20]. Decision aids varied across stud-
ies, consisting of computer, paper or video-based mate-
rials, individual, group or professionally led discussions,
tailored and general information. Decision making (includ-
ing satisfaction) and knowledge were reported, but not on
uniform outcome measures, for example, validated instru-
ments versus pragmatic study-based outcomes.
Quality of studies
Eight of the 13 trials were assessed as being of a low
methodological quality, with five trials assessed as being
of a medium quality (Table 2). Only one study, Gattellari
[21], was double-blinded. In this instance, blinding of
participants and investigators may be difficult to achieve
given the nature of the intervention under investigation.
Despite this limitation, the majority of studies were lim-
ited in their attempt to control for allocation concealment,
achieved by six studies, and intention-to-treat analysis,
achieved only by three studies.
Effect of interventions
The primary outcome of differences in decision making
was analysed across three sub-categories including deci-
sional satisfaction, decision-related distress (including de-
cisional conflict, anxiety) and decisional uncertainty.
Decisional satisfaction
Five studies assessed decisional satisfaction (Table 1)
[19,21–24]. Four studies compared decision aids with in-
formation only, with two demonstrating a significant in-
crease in decisional satisfaction with use of a decision
aid [19,21]. One study compared the use of decision aids
Figure 1. Flowchart for selection of inclusion of randomised controlled trials
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with usual care – concluding that a significant increase in
decisional satisfaction was associated with the use of a de-
cision aid [23].
Decision-related distress
Ten trials assessed decision-related distress, with seven tri-
als demonstrating a significant reduction in decisional
conflict/distress with use of a decision aid (Table 1) [20–
26]. Six studies compared the effectiveness of decision aids
with information only, of which two studies concluded no
significant benefit [19,27]. One study compared men receiv-
ing a tailored decision aid with a non-tailored decision aid
[19]. The second study provided the opportunity for men
in both groups to discuss the issue of prostate cancer screen-
ing with their physicians. This may have provided partici-
pants in both study arms the opportunity to allay any
concerns with their physicians. One study examining deci-
sion aids versus usual care demonstrated a significant reduc-
tion in decisional conflict/distress with a decision aid [23].
Two of the three studies comparing decision aids with no in-
formation reported a significant reduction in decisional
conflict/distress with a decision aid [20,26]. Uptake of the
decision aid in the study reporting no benefit was only
30% among participants randomised to it [28].
Decisional uncertainty
Four studies assessed decisional uncertainty, with three of
the four demonstrating no difference between a decision
aid and information only in reducing decisional uncer-
tainty (Table 1) [21,22,24]. Only one study, which com-
pared a decision aid with no information, demonstrated a
significant increase in decisional uncertainty [29].
Knowledge
All 13 studies included in this review assessed patient
knowledge (Table 1). Eleven of the 13 RCTs demonstrated
a statistically significant improvement in knowledge with
use of a decision aid [19–23,26–31]. Six studies compared
the use of a decision aid with information only, of which
four demonstrated that knowledge was significantly im-
proved in patients using the decision aid, compared with
information only [19,21,22,27]. Two studies concluded
that use of decision aids significantly increased knowledge
compared with usual care [23,30]. Five studies compared
the use of decision aids to providing no information, all
demonstrating a significant increase in knowledge in men
receiving the decision aid [20,26,28,29,31].
Of the two studies that reported no significant changes
in knowledge, one compared an entertainment approach
with decision support and to an audio booklet [24]. In this
study, the arms differed only in the decision aid arm hav-
ing included a values exercise and so this result may be
due to the similarity of the information in each arm. The
other study reporting no significant difference compared
a decision aid with tailored information versus non-
tailored information [25].
Conclusions
This systematic review identified that the methodological
quality of RCTs currently evaluating the effectiveness of
decision support for PSA testing is low to moderate at
best. Studies of a high methodological quality are urgently
required to provide patients and clinicians with strong ev-
idence on whether to utilise decision support tools for
PSA testing. Furthermore, significant heterogeneity be-
tween the studies with respect to the design of the inter-
vention and its implementation rule out the pooling of
data and direct comparisons across studies. The studies in-
cluded in this systematic review demonstrate an effect for
knowledge and decision-related distress and so can be rec-
ommended with the previously stated caveats in mind.
Only one systematic review to date (published in 2007)
has specifically investigated the impact of decision aids
Table 2. Methodological quality of included studies
Blinding
Allocation
concealment
Intention to treat
analysis (ITT)
Generation of
allocation sequencea
Overall
rating
Allen 2010 [28] 1 0 0 1 Low
Chan 2011 [29] 1 2 2 1 Medium
Evans 2010 [26] 1 2 0 0 Low
Gattellari 2003 [21] 2 0 1 0 Low
Gattellari 2005 [22] 1 2 2 1 Medium
Lepore 2012 [20] 1 2 1 1 Medium
Myers 2011 [27] 1 1 1 0 Medium
Partin 2004 [30] 1 2 0 1 Low
Sheridan 2012 [31] 1 1 2 1 Medium
Taylor 2013 [23] 0 0 0 1 Low
Volk 2008 [24] 1 0 0 0 Low
Watts 2013 [19] 0 2 0 1 Low
Williams 2013 [25] 1 0 0 0 Low
aNot considered when calculating the overall evidence quality rating.
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for prostate cancer screening [32]. Findings from that re-
view concluded that decision aids increased patient
knowledge and confidence in decision making. The results
from our review support those findings. The 2007 review
also identified that the use of decision aids significantly
decreased men’s interest in PSA testing and screening be-
haviour (relative risk [RR]=0.88, 95% confidence inter-
vals [CI]= 0.81–0.97). [32]. A 2014 update of a
Cochrane systematic review on decision aids for people
facing screening or treatment decisions (across a variety
of health conditions) supported the findings that decision
aids increase patient knowledge and decrease decisional
conflict [13]. Furthermore, because of the long natural his-
tory of prostate cancer, a conclusive survival benefit is
warranted before recommending testing for early disease.
Our systematic review differs from the Volk and Stacey
reviews [13,32], as it deals specifically with decision aids
and tailored information for PSA screening. Volk con-
siders more general ‘educational interventions’ for PSA
screening and Stacey focuses on screening behaviours in
the context of PSA screening, but examines the other as-
pects of decision making and patient knowledge only in
the context of screening in general not in the context of
PSA screening. No meta-analysis was performed in our re-
view because of the heterogeneity of the decision aids and
comparisons. The presumption of homogeneity between
studies, when it is not apparent, can alter statistical conclu-
sion by up to 20% [33]. Despite the presence of such clin-
ical heterogeneity, our results support (albeit descriptively)
previous conclusions that decision aids support patient
knowledge and confidence in decision making [13,32].
Given that the current evidence suggests that decision
aids are effective at increasing patient knowledge and im-
proving a patient’s decision-making process, the next step
is to ensure their successful implementation into clinical
practice. For research to be successfully implemented, it
must work its way through the ‘evidence pipeline’, which
does not always ensure uptake into practice [34]. A four-
step process has been suggested for the successful imple-
mentation of a decision aid, which includes (i) meeting
the needs of the population, (ii) willingness of practi-
tioners to utilise it in clinical practice, (iii) the presence
of effective systems, and (iv) practitioners and consumers
skilled in shared decision making [13]. Successful imple-
mentation of this modelled approach requires a tailored
approach, accounting for other external factors aligned
with a patient’s level of health literacy and an ability to
objectively assess other issues which, in prostate cancer
includes a realistic estimation of life expectancy.
Clinicians are commonly supportive towards the use of
decision aids in practice [35], particularly in a field such as
prostate cancer in which the effectiveness of the interven-
tion is questionable, the appropriateness of the advice un-
certain and in which patient preferences play an important
role [36]. However, intention to use does not align with
actual use of decision aids in clinical practice [35]. Re-
strictions on practitioner time, awareness and access to de-
cision aids and skill in utilising them with patients in a
clinical environment have all been identified as barriers
to successful implementation of decision aids in clinical
practice [37–40].
Critical to successful implementation of decision aids in
practice is the support of clinical staff (physicians and
nursing staff) as well as administrative staff [41]. Yet,
the main barrier to successful implementation still remains
the first step in the ‘evidence pipeline’ – a lack of practi-
tioner awareness about decision aids and their effective-
ness [42]. Options for overcoming this barrier include
automatic distribution of decision aids and the engage-
ment of members other than physicians for their use
[43]. Although still in its infancy, the use of practice-
nurses to engage with patients in discussion about PSA
testing with the assistance of decision aids has been effec-
tive in implementing the use of decision aids in clinical
practice and promoting shared decision making between
patients and practitioners [27].
This systematic review consisted of published data
only, with outcomes limited to decision making and pa-
tient knowledge. Impact of decision aids upon uptake of
PSA testing, or prostate cancer screening generally, was
not assessed as the current evidence from systematic re-
views of the literature conclude no significant reduction
in prostate-specific, or all-cause, mortality [4]. Studies in-
cluded in this systematic review were undertaken with
populations from the US, UK and Australia with some
US studies including Hispanic and African American pop-
ulations. The evidence is generalizable to well men in
Western countries who are considering PSA testing with
some reservations in considering how effective these in-
terventions may be for men with low levels of education
and low literacy; from a non-English speaking back-
ground; or other minority or cultural groups.
Future research is required to further examine the effec-
tiveness of decision aids across these populations, as well
as various other ethnic groups including African and Asian
populations. In addition to identifying successful models
for implementing decision aids in clinical practice, further
research is also required to determine equivalency between
different modes of delivery, be it decision aid-related (i.e.
written, audio-visual, web-based), or implementation-
related (i.e. patient self-directed use or facilitated by prac-
titioners) [44]. The continued long-term follow-up of pa-
tients from large prostate cancer screening and prevention
trials has identified data that has been utilised in the devel-
opment of prostate cancer risk calculators [45,46]. Further
research into the effectiveness of such tailored risk identi-
fication is also required, along with the influence of patient
health literacy, to truly underpin the benefit of these deci-
sion aids in providing information about PSA testing and
prostate cancer to men.
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